Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.
Revenue (Most Recent Fiscal Year) | $3.31M |
Net Income (Most Recent Fiscal Year) | $-8.24M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 5.73 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.65 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -424.10% |
Net Margin (Trailing 12 Months) | -142.62% |
Return on Equity (Trailing 12 Months) | -39.89% |
Return on Assets (Trailing 12 Months) | -25.45% |
Current Ratio (Most Recent Fiscal Quarter) | 5.57 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.57 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $1.58 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 8.90M |
Free Float | 6.76M |
Market Capitalization | $37.30M |
Average Volume (Last 20 Days) | 0.02M |
Beta (Past 60 Months) | 1.50 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 24.10% |
Percentage Held By Institutions (Latest 13F Reports) | 22.39% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |